(Q36648725)

15 August 2017

1 reference

title

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model (English)

1 reference

cost-effectiveness analysis

15 August 2017

0 references

1 reference

Zethraeus N

1

1 reference

15 August 2017

Borgström F

2

1 reference

15 August 2017

Ström O

3

1 reference

15 August 2017

Kanis JA

4

1 reference

15 August 2017

Jönsson B

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

9 November 2006

1 reference

Osteoporosis International

15 August 2017

published in

1 reference

15 August 2017

volume

18

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

9-23

1 reference

Estrogen use in postmenopausal women--costs, risks, and benefits

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

Variations in population health status: results from a United Kingdom national questionnaire survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

The impact of hormone replacement therapy on quality of life and willingness to pay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-006-0257-0

Accounting for future costs in medical cost-effectiveness analysis

21 January 2018

1 reference

12 December 2020

Effect and offset of effect of treatments for hip fracture on health outcomes

1 reference

12 December 2020

Excess mortality after hospitalisation for vertebral fracture

1 reference

12 December 2020

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

1 reference

12 December 2020

The components of excess mortality after hip fracture

1 reference

12 December 2020

Cost-effectiveness of bisoprolol in chronic heart failure

1 reference

12 December 2020

Mortality after osteoporotic fractures

1 reference

12 December 2020

The cost utility of bisphosphonate treatment in established osteoporosis

1 reference

12 December 2020

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

1 reference

12 December 2020

Cost-effectiveness of hormone replacement therapy in the menopause.

1 reference

12 December 2020

Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Swedish population health-related quality of life results using the EQ-5D.

1 reference

12 December 2020

12 Cost-effectiveness of hormone replacement therapy after the menopause

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study

1 reference

12 December 2020

Costs and quality of life associated with osteoporosis-related fractures in Sweden.

1 reference

12 December 2020

Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents.

1 reference

12 December 2020

The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

The cost of a hip fracture. Estimates for 1,709 patients in Sweden

1 reference

12 December 2020

Cost-effectiveness of hormone replacement

1 reference

12 December 2020

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

1 reference

12 December 2020

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature

1 reference

12 December 2020

Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application

1 reference

12 December 2020

What is the true mortality of hip fractures?

1 reference

12 December 2020

Cost-effectiveness of fracture prevention treatments in the elderly.

1 reference

12 December 2020

Handling uncertainty in cost-effectiveness models

1 reference

12 December 2020

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study

1 reference

12 December 2020

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden

1 reference

12 December 2020

Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

Pharmacoeconomic analysis of osteoporosis treatment with risedronate.

1 reference

12 December 2020

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

1 reference

12 December 2020

Measuring the impact of menopausal symptoms on quality of life

1 reference

12 December 2020

Population-based study of survival after osteoporotic fractures

1 reference

12 December 2020

Effect of external hip protectors on hip fractures

1 reference

12 December 2020

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden

1 reference

12 December 2020

Lifetime risk of hip fractures is underestimated

1 reference

12 December 2020

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Risk of Mortality Following Clinical Fractures

1 reference

12 December 2020

Cost-effectiveness of fracture prevention in established osteoporosis.

1 reference

12 December 2020

A computer model to analyze the cost-effectiveness of hormone replacement therapy

1 reference

12 December 2020

Cost-effectiveness of hip protectors in institutional dwelling elderly.

1 reference

12 December 2020

The risk and burden of vertebral fractures in Sweden

1 reference

12 December 2020

Cost and effectiveness of hip protectors among the elderly

1 reference

12 December 2020

Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden

1 reference

12 December 2020

Economic evaluation of osteoporosis prevention

1 reference

12 December 2020

Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age

1 reference

12 December 2020

Long-term risk of osteoporotic fracture in Malmö.

1 reference

12 December 2020

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy

1 reference

12 December 2020

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

1 reference

12 December 2020

Predictive Value of BMD for Hip and Other Fractures

1 reference

12 December 2020

Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective

1 reference

12 December 2020

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

1 reference

12 December 2020

Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

1 reference

12 December 2020

Association between vertebral fracture and increased mortality in osteoporotic patients

1 reference

12 December 2020

Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment

1 reference

12 December 2020

Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women

1 reference

12 December 2020

Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures

1 reference

12 December 2020

10.1007/S00198-006-0257-0

Identifiers

DOI

1 reference

15 August 2017

1 reference